Prospects and advances in hormonal immunomodulatory therapy

Bailliere's Clinical Rheumatology

Volumn 10, Issue 2, 1996, Pages 379-392

  Jorgensen, C ^a   Sany, J ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BROMOCRIPTINE; CATECHOLAMINE; CORTICOTROPIN; CYCLOSPORIN A; CYPROTERONE; DANAZOL; ESTROGEN; NEUROPEPTIDE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE;

ARTHRITIS; AUTOIMMUNITY; CLINICAL ARTICLE; ETIOLOGY; FEMALE; HORMONAL THERAPY; HUMAN; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS;

EID: 0029884506     PISSN: 09503579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3579(96)80023-9     Document Type: Article

References (100)

1. Agnello V, Panser K, Gell Jet al (1983) Preliminary observation in danazol therapy of systemic lupus erythematosus effects on DNA antibodies thrombocytopenia and complement. Journal of Rheumatology 10: 682-687.
2. Ahokas RA, Seydoux J, Llanos et al (1985) Hypothalamic opiods and the acute phase glycoprotein response in guinea pigs. Brain Research Bulletin 15: 603-608.
3. Ansar Ahmed S & Talal N (1989) Sex hormones and autoimmune rheumatic disorders. Scandinavian Journal of Rheumatology 18: 69-76.
4. Arden NK, Lloyd ME, Spector TD & Hughes GR (1994) Safety of hormone replacement therapy in systemic lupus erythematosus. Lupus 3: 11-13.
5. Ballieux RE (1992) Bidirectional communication between the brain and the immune system. European Journal of Clinical Investigations 22: 6-9.
6. Berczi I, Nagy E, Asa S & Kovacs K (1984) The influence of pituitary hormones on adjuvant arthritis. Arthritis and Rheumatism 27: 682-688.
7. Blatteis CM (1990) Neuromodulative actions of cytokines. Yale Journal of Biology and Medicine 63: 133-146.
8. Boumpas DT, Austin HA, Fessler BJ & Balow JE (1995) Systemic lupus erythematosus: emerging concept. Annals of lnternal Medicine 123: 42-53.
9. Bravo G, Zazueta B & Lavalle C (1992) An acute remission of Reiter's syndrome in male patients treated with bromocriptine. Journal of Rheumatology 19: 747-750.
10. Brennan P & Silman A. (1994) Breast feeding and the onset of rheumatoid arthritis. Arthritis and Rheumatism 37:808-813.
11. Bringer J, Monabeka H, Perfin Bet al (1990) Gonadotropin-releasing hormone agonist: a useful therapy in internal medicine. In P Bouchard P & Haaour F (eds) Recent Progress on GnRH and Gonadal Peptides, pp 331-339. Paris: Elsevier.
12. Buskila D, Berezin M, Gur Het al (1995) Autoantibody profile in the sera of women with hyperprolactinemia. Journal of Autoimmunity 8: 415-424.
13. Cash JM, Crofford LJ, Gallucci WT et al (1992) Pituitary adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone. Journal of Rheumatology 19: 1692-1696.
14. Catania A, Mangone I, Motta P & Zanussi C (1989) Administration of gonadotrophin releasing hormone analog as adjunctive therapy in women with systemic lupus erythematosus. Arthritis and Rheumatism 32: 1186-1188.
15. Chemilcka-Schorr E, Kwasniewski MN, Thomas BE & Arnason BG (1989) The beta-adrenergic agonist isoproterenol suppresses experimental allergic encephalomyelitis in Lewis rats. Journal of Neuroimmunology 25: 203-207.
16. Chikanza IC & Panayi GS (1991) Hypothalamic-pituitary mediated modulation of immune function: prolactin as a neuroimmune peptide. British Journal of Rheumatology 30: 203-207.
17. Chikanza IC, Petrou P, Kingsley Get al (1992) Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis and Rheumatism 35: 1281-1288.
18. Chrousos GP, Wilder RL & Gold PW (1992) The stress response and the regulation of the inflammatory disease. Annals of Internal Medicine 117: 854-866.
19. Conconi MV & Walker AM (1984) Chloroquine affects prolactin secretion and golgi morphology in mammotroph. Endocrinology 114: 725-734.
20. Cutolo M & Aceardo S (1991) Sex hormones, HLA and rheumatoid arthritis. Clinical and Experimental Rheumatology 9: 641-646.
21. Cutolo M, Accardo S & Villaggio (1992) Evidence for the presence of androgen receptor in the synovial tissue of rheumatoid arthritis patients. Arthritis and Rheumatism 35: 1007-1015.
22. Cutolo M, Balleari E, Giusti Met al (1991) Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis and Rheumatism 34: 1-5.
23. da Silva JA, Larbre JP, Seed MP et al (1994) Sex differences in inflammation in rodents. The influence of sex steroids. Journal of Rheumatology 21: 330-337.
24. Dougados M, Duchesne L & Amor B (1988) B romocriptine and cyclosporin combination therapy for rheumatoid arthritis. Arthritis and Rheumatism 31: 1333-1339.
25. Dougados M, Amor B, Job Deslandre C & Menkes CJ (1985) Danazol in systemic lupus erythematosus: a 2 years prospective controlled trial in 40 female patients. Arthritis and Rheumatism 28: S46.
26. Eulry F, Bauduceau B, Bouée Set al (1994) Réponse de la prolactine à la protiré1ine au cours des arthrities reactionelles et de la spondylarthrite ankylosante. Reviews of Rheumatology and Osteoarthritis 11: 863-864.
27. Feher K & Feher T (1984) Plasma DHA, DHAS and androsterone sulfate levels and their interactions with plasma proteins in RA. Experimental arm Clinical Endocrinology 84" 117-202.
28. Ferrari C, Boghen M & Cesano A (1983) Thyroid autoimmunity in hyperprolactinemic disorders? Acta Endocrinologica 104: 35-41.
29. Garcia I, Perez Castillo A, Moreno J & Alemany C (1992) Beta endorphin inhibit IL2 release and expression of IL2 receptor in Con A stimulated splenic lymphocyte. Lymphokine and Cytokine Research 11: 339-345.
30. Gebel HM, Braun DP, Rotman C et al (1993) Mitogen induced production of polyclonal IgG is decreased in women with severe endometriosis. American Journal of Reproductive Immunology 29: 124-130.
31. Gutierrez MA, Cabrera GE, Cuellar ML et al (1993) Prolactin induces autoantibody formation by PBL of normal individuals and SLE patients. Arthritis and Rheumatism 36: S197.
32. Hazes JMW, Dijkmans BAC & Vandenbroucke JP (1989) oral contraceptive treatment for rheumatoid arthritis: an open study of 10 female patients. British Journal of Rheumatology 28: 28-30.
33. Hazes JMW, Dijkmans BAC, Vandenbroucke JP et al (1990) Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis and Rheumatism 33: 173-179.
34. Hazleton RA, McGruder AB, Sturrock RD & Stimson WH (1983) Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone. Annals of Rheumatic Disease 42:155-157.
35. Hedman M, Nilsson E & DelaTorre B (1989) Low sulphoconjugated steroid hormone levels in systemic lupus erythematosus. Clinical and Experimental Rheumatology 7: 83-88.
36. Hedner LP & Bynke G (1985) Endogenous iridocyclitis relieved during treatment with bromcriptine. American Journal of Opthpalmology 100: 618-619.
37. Hiestand PC, Gale JM & Mekler P (1986) Soft immunosuppression by inhibition of prolactin release: synergism with cyclosporine in kidney allograft survival. Transplant Proceedings 18: 870-872.
38. Hooghe R, Delhase M, Vergani Pet al (1993) Growth hormone and prolactin are paracrine growth and differentiation factors in the haemopoietic system. Immunology Today 14: 212-214.
39. Jara LJ, Lavalle C, Fraga A et al (1991) Prolactin, immunoregulation, and autoimmune disease. Seminars in Arthritis and Rheumatology 20: 273-284.
40. Jara-Quezada L, Graef A & Lavalle C (1991) Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. Journal of Rheumatology 18: 349-353.
41. Jorgensen C, Bressot N, Lefebre Pet al (1995a) Dysregulation of the pituitary adrenal axis and of the pituitary prolactin synthesis in rheumatoid arthritis. Journal of Rheumatology 22: 1829-1833.
42. Jorgensen C, Picot MC, Bologna C & Sany J (1995b) Oral contraception, parity, breast feeding and severity of rheumatoid arthritis. Annals of Rheumatic Disease (in press).
43. Jungers P, Dougados M, Pelissier C et al (1982) Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis and Rheumatism 25: 618-623.
44. Jungers P, Kutten F, Lioté F et al (1985) Hormonal modulation in systemic lupus erythematosus. Preliminary clinical and hormonal results with cyproterone acetate. Arthritis and Rheumatism 28: 1243-1250.
45. Kaplan R, Robinson CA, Scavuli JF & Vanghan J H (1980) Propranolol and the treatment of rheumatoid arthritis. Arthritis and Rheumatism 23: 253-255.
46. Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. New England Journal of Medicine 333: 142-146.
47. Lahita GR, Cheng CY, Monder C & Bardin CW (1992) Experience with 19-nortestosterone in the therapy of systemic lupus erythematosns: worsened disease after treatment with 19-nortestosterone in men and lack of improvement in women. Journal of Rheumatology 19: 547-555.
48. Larsson J, Ekblom A, Henriksson K et al, (1991) Concentration of substance P, neurofinin A, calcitonin gene related peptide, neuropeptide Y, and VIP in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scandinavian Journal of Rheumatology 20: 326-335.
49. Lavalle C, (1992) Prolactin: a hormone with immunoregulatory properties that leads to new therapeutic approaches in rheumatic disease. Journal of Rheumatology 19: 839-841.
50. Lavalle C, Loyo E & Paniagua R (1987) Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. Journal of Rheumatology 14: 268-272.
51. Levine JD, Coderre TJ, Helms C & Basbaum AI (1988) Beta adrenergic mechanisms in experimental arthritis. Proceedings of the National Academy of Science, USA 85: 4553-4555.
52. Levine JD, Fye K, Heller Pet al (1986) Clinical response to regional intravenous guanethidine in RA. Journal Rheumatology 13: 1040-1043.
53. Linos A, Worthington JW & O'Fallon WN (1983) Case control study of rheumatoid arthritis and prior use of oral contraceptive. Lancet i: 1299-1300.
54. Lioté F, Dehaine V, Pelissier C et al (1991) Hormonal modulation with cyproterone acetate in systemic lupus erythematosus: long term follow-up study. Arthritis and Rheumatism 28: S 187.
55. Lotz M, Carson DA & Vaughan JH (1987) Substance P activation of rheumatoid synoviocytes: a neural pathway in the pathogenesis of arthritis. Science 235: 893-895.
56. Lucas JA, Ahmed SA, Casey ML & McDonald PC (1985) Prevention of autoantibody formation and prolonged survival in NZW/NZB F1 mice fed DHAS. Journal of Clinical Investigations 75:2091-2099.
57. Mann DR, Ansari AA, Akinbami MA et al (1994) Neonatal treatment with luteinizing hormonereleasing hormone analogs alters peripheral lymphocyte subsets and cellular and humorally mediated immune responses in juvenile and adult male monkeys. Journal of Clinical and Endocrinological Metabolism 78: 292-298.
58. Martens HF, Sheet PK, Tenover JS et al (1994) Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy. Journal of Rheumatology 21: 1427-1431.
59. Matucci M & Partsch G (1992) Peripheral nervous system and neuropeptide network in synovial inflammation. Clinical and Experimental Rheumatology 10: 211-215.
60. Matucci M, Lotti T, Cappugi P ct al (1988) Somatostatin treatment of psoriasic arthritis. Pharmacological Therapy 27: 56-58.
61. McDonach JE, Singh MM & Griffiths ID (1993) Menstrual arthritis. Annals of Rheumatic Disease 52: 65-66.
62. McMurray R, Allen SH, Braun AL et al (1994a) Longstanding hyperprolactinemia associated with systemic lupus erythematosus. Journal of Rheumatology 21: 843-850.
63. McMurray R & Keisler D (1991) Prolactin influences autoimmune disease activity in the female B/W mice. Journal of Immunology 147: 3780-3787.
64. McMurray R, Weidensaul D, Allen SH & Walker SE (1994b) Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. Arthritis and Rheumatism 37: S369.
65. Montgomery D, Zukovski C, Shah G & Con A (1987) stimulated murine splenocytes produce a factor with prolactin like bioactivity and immunoreactivity? Biochemical Biophysical Research Communications 145: 692-698.
66. Nagy E, Chalmers IM, Baragar FD et al (1991) Prolactin deficiency in rheumatoid arthritis. Journal of Rheumatology 18: 1662-1668.
67. Neeck G, Federlin K, Graif Vet al (1990) Adrenal-secretion of cortisol in patients with rheumatoid arthritis. Journal of Rheumatology 17: 24-29.
68. Oka M (1953) Effect of pregnancy on the onset and course of rheumatoid arthritis. Annals of Rheumatic Disease 73: 227-229.
69. Palestine AG, Nussenblatt RB & Gelato MC (1988) Therapy for human autoimmune uveitis with low dose cyclosporine plus bromocriptine. Transplant Proceedings 20:131-135.
70. Palestine AG, Muellenberg CG, Kim MK et al (1987) Bromocriptine and low dose cyclosporine in the treatment of experimental autoimune uveitis in rats. Journal of Clinical Investigations 79:1078-1081.
71. Panayi GS (1993) A defect in the neuroendocrine axis in rheumatoid arthritis: pathogenetic implications. Clinical Experimental Rheumatology 11: S83-S85.
72. Payan DG, Hess CA & Goetzl EJ (1984) Inhibition by somatostatin of the proliferation of T lymphocytes and MOLT 4 lymphocytes. Cell Immunology 84: 433-439.
73. Rees RG, Eckland DJ, Lightman SL & Brewerton DA (1989) The effect of somatostatin analogue BM23014 on adjuvant arthritis in rats. British Journal of Rheumatology 28: 40-41.
74. Reichlin S (1993) Neuroendocrine-immune interactions. New England Journal of Medicine 329: 1246-1253.
75. Roubinian JR, Talal N, Greenspan JS et al (1979). Danazol failure to suppress autoimmunity in NZB/NZW F1 mice. Arthritis and Rheumatism 22: 1399-1402.
76. Roubinian JR, Talal N, Greenspan JS et al (1978) Effect of castration and sex hormones treatment on survival, antinncleic acid antibodies and glomerulonephritis in NZB/NZW F1 mice. Journal of Experimental Medicine 147: 1568-1583.
77. Rubinovitch CE, Shanberg L & Kredich D (1990) Intravenous immunoglobulin and bromocriptin in the treatment of refractory SLE. Arthritis and Rheumatism 33:22 (abstract).
78. Russell DH, Larson DF & Womble JR (1983) Cyclosporin A inhibits omithine deearboxylase induction in kidney in response to prolactin, growth hormone and insulin. Physiologist 26: A13.
79. Sambrook PN, Eisman JA, Champion GD & Pocock NA (1988) Sex hormones status and osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis and Rheumatism 31: 973-977.
80. Sanchez-Guerrero J, Liang M, Karlson EW et al (1995) Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Annals oflnternal Medicine 122: 430-433.
81. Spector TD & Hochberg MC (1990) The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. Journal of Clinical Epidemiology 43" 1221-1230.
82. Spector TD, Roman E & Silman AJ (1988) Low free testosterone levels in rheumatoid arthritis. Annals of Rheumatic Disease 47: 65-68.
83. Spector TD, Perry LA, Tub G & Silman AJ (1990) The pill, parity, and rheumatoid arthritis. Arthritis and Rheumatism 33" 782-789.
84. Sternberg EM, Hill JM & Chrousos GP (1989a) Inflammatory mediator induced hypothalamic pituitary adrenal axis activation is defective in streptococcal cell wall-induced arthritis in Lewis rats. Proceedings of the National Academy of Sciences, USA 86: 2374-2378.
85. Sternberg EM, Young WS, Bernardini R et al (1989b) A central nervous system defect in the synthesis of CRH is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proceedings of the National Academy of Sciences, USA 86: 4771-4775.
86. Sturgess A, Evans DT, Mackay IR & Riglar A (1984) Effects of the estrogen antogonist tamoxifen on disease indices in systemic lupus erythematosus. Journal of Clinical and Laboratory Immunology 13:11-14.
87. Surman OS (1993) Possible immunological effects of psychotropic medication. Psychosomatics 34: 139-143.
88. Van den Berg P, Rozing J & Nagelkerken L (1993) Beta endorphin stimulates la expression on mouse B cells by inducing IL4 secretion by CD4 T cells. Cell Immunology 149: 180-192.
89. Vandenbroucke JP, Witteman JCM, Valkenbourg HA et al (1986) Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and post menopausal women. Journal of the American MedicaIAssociation 255: 1299-1303.
90. VanVollenhoven RF, Engleman EG & McGuire JL (1994a) An open study of DHAS in systemic lupus erythematosus. Arthritis and Rheumatism 37: 1305-1310.
91. VanVollenhoven RF, Morabito LM, Engleman EG et al (1994b) Treatment of systemic lupus erythematosus with DHAS. Follow up data from a double blinded randomized placebo controlled clinical trial. Arthritis and Rheumatism 37: S369.
92. Van Zeben D, Hazes JAW, Vandenbroucke JP et al (1990) Diminished incidence of severe rheumatoid arthritis associated with oral contraceptive use. Arthritis and Rheumatism 33: 1462-1465.
93. Verheul H, Stimson WH, Hollander FC & Schuurs A (1981) The effect of nandrolone, testosterone and their decanoate esters on murine lupus. Clinical and Experimented Immunology 94:11-17.
94. Viselli SM & Mastro AM (1993) Prolactin is found on heterogeneous subp0pulations of rat splenocytes. Endocrinology 132:3027-3031.
95. Wallace DJ (1993) Management and prognosis of lupus. In Wallace DJ & Hahn BH (eds) Dubois's lupus erythematosus, pp 601-602. Philadelphia: Lea and Febiger.
96. Weber G & Frey H (1986) Results of treatment of psoriasic arthritis with bromocriptine. Z. Hautkr 61: 1456-1466.
97. West SG & Johnson SC (1988) Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Annals of Internal Medicine 108: 703-706.
98. Whyte A & Williams RO (1988) Bromocriptin suppresses postpartum exacerbation of collagen induced arthritis. Arthritis and Rheumatism 31: 927-928.
99. Wilder RL, Calandra GB, Garvin AJ et al (1982) Strain and sex variation in the susceptibility to streptococcal cell wall-induced arthritis in the rat. Arthritis and Rheumatism 25: 1064-1072.
100. Wilner ML, Ettenger RB, Koyle MA & Rosenthal JT (1990) The effect of hypoprolactinemia alone or in combination with cyclosporin on allograft rejection. Transplantation 49: 264-267.